SI2480546T1 - Derivati imidazopiridina ali imidazopirimidina kot inhibitorji fosfodiesteraze 10a - Google Patents

Derivati imidazopiridina ali imidazopirimidina kot inhibitorji fosfodiesteraze 10a

Info

Publication number
SI2480546T1
SI2480546T1 SI201030869T SI201030869T SI2480546T1 SI 2480546 T1 SI2480546 T1 SI 2480546T1 SI 201030869 T SI201030869 T SI 201030869T SI 201030869 T SI201030869 T SI 201030869T SI 2480546 T1 SI2480546 T1 SI 2480546T1
Authority
SI
Slovenia
Prior art keywords
imidazopyridine
phosphodiesterase
inhibitors
imidazopyrimidine derivatives
imidazopyrimidine
Prior art date
Application number
SI201030869T
Other languages
English (en)
Inventor
Daniela Alberati
Sanchez Ruben Alvarez
Konrad Bleicher
Alexander Flohr
Zbinden Katrin Groebke
Matthias Koerner
Bernd Kuhn
Jens-Uwe Peters
Markus Rudolph
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of SI2480546T1 publication Critical patent/SI2480546T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
SI201030869T 2009-09-24 2010-09-21 Derivati imidazopiridina ali imidazopirimidina kot inhibitorji fosfodiesteraze 10a SI2480546T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09171253 2009-09-24
PCT/EP2010/063830 WO2011036127A1 (en) 2009-09-24 2010-09-21 Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors
EP10760968.7A EP2480546B1 (en) 2009-09-24 2010-09-21 Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10A inhibitors

Publications (1)

Publication Number Publication Date
SI2480546T1 true SI2480546T1 (sl) 2015-03-31

Family

ID=43416552

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201030869T SI2480546T1 (sl) 2009-09-24 2010-09-21 Derivati imidazopiridina ali imidazopirimidina kot inhibitorji fosfodiesteraze 10a

Country Status (22)

Country Link
US (2) US8017604B2 (sl)
EP (1) EP2480546B1 (sl)
JP (1) JP5629322B2 (sl)
KR (1) KR101426624B1 (sl)
CN (1) CN102548991B (sl)
AR (1) AR078437A1 (sl)
BR (1) BR112012006531A2 (sl)
CA (1) CA2770087C (sl)
CL (1) CL2012000708A1 (sl)
CY (1) CY1116120T1 (sl)
DK (1) DK2480546T3 (sl)
ES (1) ES2530884T3 (sl)
HR (1) HRP20150345T1 (sl)
IL (1) IL218032A (sl)
MX (1) MX2012003469A (sl)
PE (1) PE20121438A1 (sl)
PL (1) PL2480546T3 (sl)
PT (1) PT2480546E (sl)
RU (1) RU2502737C2 (sl)
SI (1) SI2480546T1 (sl)
TW (1) TWI402268B (sl)
WO (1) WO2011036127A1 (sl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470820B2 (en) * 2010-01-22 2013-06-25 Hoffman-La Roche Inc. Nitrogen-containing heteroaryl derivatives
TW201242965A (en) * 2011-02-01 2012-11-01 Kyowa Hakko Kirin Co Ltd Ring-fused heterocyclic derivative
SG192839A1 (en) 2011-02-18 2013-09-30 Allergan Inc Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
US8975276B2 (en) 2011-06-29 2015-03-10 Bristol-Myers Squibb Company Inhibitors of PDE10
EP2574607A1 (en) 2011-09-06 2013-04-03 F. Hoffmann-La Roche AG PDE10 modulators
PE20141553A1 (es) * 2011-09-19 2014-10-30 Hoffmann La Roche Compuestos de triazolopiridina como inhibidores de la ped10a
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
JP2016513083A (ja) * 2013-01-31 2016-05-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 放射標識された化合物
PT2963037T (pt) 2013-02-27 2019-04-23 Mochida Pharm Co Ltd Novo derivado de pirazole
SI2991983T1 (sl) 2013-04-29 2017-06-30 F. Hoffmann-La Roche Ag DERIVATI 2-FENIL ALI 2-HETARIL IMIDAZOL(1,2-a)PIRIDINA
MY169128A (en) * 2013-04-30 2019-02-18 Hoffmann La Roche Pd-catalyzed coupling of pyrazole amides
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
CA2920068A1 (en) * 2013-09-26 2015-04-02 F. Hoffmann-La Roche Ag Imidazo[1,2-a]pyridin-7-amines as imaging tools
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
TWI750218B (zh) 2016-09-02 2021-12-21 美商賽克瑞恩醫療公司 sGC 刺激劑
CN113698406A (zh) * 2021-08-30 2021-11-26 成都药明康德新药开发有限公司 6-甲基吡唑并[1,5-a]嘧啶-3-胺的合成方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK9892001A3 (en) * 1999-11-10 2002-04-04 Ortho Mcneil Pharm Inc Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a]pyrimidines, and related pharmaceutical compositions and methods
SE0102808D0 (sv) * 2001-08-22 2001-08-22 Astrazeneca Ab New compounds
CA2492138C (en) * 2002-07-12 2011-01-11 Yamanouchi Pharmaceutical Co., Ltd. N-phenyl-(2r,5s)dimethylpiperazine derivative
US20060106054A1 (en) * 2002-12-03 2006-05-18 Michiaki Nagasawa Phosphodiesterase 10a inhibitors
WO2005012485A2 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
JPWO2005108399A1 (ja) * 2004-05-10 2008-03-21 萬有製薬株式会社 イミダゾピリジン化合物
WO2006094235A1 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
EP1979350A1 (en) * 2006-01-17 2008-10-15 F.Hoffmann-La Roche Ag Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of alzheimer's disease via gaba receptors
WO2007098169A1 (en) 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
FR2926556B1 (fr) * 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
BR112012006531A2 (pt) 2016-11-22
JP5629322B2 (ja) 2014-11-19
AU2010299927A1 (en) 2012-03-15
MX2012003469A (es) 2012-04-19
AR078437A1 (es) 2011-11-09
PT2480546E (pt) 2015-02-09
JP2013505911A (ja) 2013-02-21
CY1116120T1 (el) 2017-02-08
KR101426624B1 (ko) 2014-08-05
RU2502737C2 (ru) 2013-12-27
CN102548991B (zh) 2015-03-25
WO2011036127A1 (en) 2011-03-31
EP2480546A1 (en) 2012-08-01
PE20121438A1 (es) 2012-10-26
IL218032A0 (en) 2012-04-30
EP2480546B1 (en) 2014-12-31
CN102548991A (zh) 2012-07-04
TWI402268B (zh) 2013-07-21
CA2770087C (en) 2014-09-09
KR20120068943A (ko) 2012-06-27
CA2770087A1 (en) 2011-03-31
CL2012000708A1 (es) 2012-09-07
US20110071128A1 (en) 2011-03-24
US20110294779A1 (en) 2011-12-01
HRP20150345T1 (hr) 2015-05-08
RU2012113128A (ru) 2013-11-10
DK2480546T3 (en) 2015-02-02
IL218032A (en) 2014-06-30
PL2480546T3 (pl) 2015-05-29
ES2530884T3 (es) 2015-03-06
US8263584B2 (en) 2012-09-11
US8017604B2 (en) 2011-09-13
TW201116530A (en) 2011-05-16

Similar Documents

Publication Publication Date Title
IL218032A0 (en) Imidazopyridine or imidazopyrimidine derivatives as phosphodiesterase 10a inhibitors
HK1219950A1 (zh) 作爲激酶抑制劑的吡咯並吡啶
ZA201203326B (en) Imidazopyridine derivatives as jak inhibitors
IL195010A0 (en) Bicyclic derivatives as cetp inhibitors
IL212285A0 (en) Azaindole derivatives
HK1156026A1 (en) Pyrazolopyridine kinase inhibitors
IL215297A0 (en) Imidazopyrazines for use as kinase inhibitors
IL216145A0 (en) Dihydropyrimidinones for use as bace2 inhibitors
HK1170377A1 (en) Substituted xanthine derivatives
IL212842A0 (en) Azaindole derivatives as kinase inhibitors
IL210172A0 (en) Substituted pyrimidin-4-one derivatives
IL211241A0 (en) 7-azaindole derivatives
GB201016880D0 (en) Phosphodiesterase inhibitors
EP2486039A4 (en) HSP90 INHIBITORS SUITABLE PURE DERIVATIVES
IL224903A (en) Imidzo [c – 5,4] quinolines as DNA inhibitors
HK1177739A1 (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors pde10a 2-
SI2124944T1 (sl) Derivati pirazolo b piridina kot inhibitorji fosfodiesteraze
ZA201105896B (en) [1,2,4] triazolo [1,5-a] pyridines as kinase inhibitors
EP2379538A4 (en) HETEROCYCLIC COMPOUNDS AS A PHOSOPHODIESTERASE HEMMER
SI3070091T1 (sl) Derivati benzodioksola kot zaviralci fosfodiesteraze
EP2473052A4 (en) SUBSTITUTED XANTHINE DERIVATIVES
IL219603A0 (en) Imidazopyridine derivatives
EP2318401A4 (en) AZAINDOLI INHIBITORS OF IPA
GB0918924D0 (en) Azaindole derivatives